Genetic Aspects of Alzheimer Disease

The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.

EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease

Now Viewing

EP: 3.Genetic Aspects of Alzheimer Disease

EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease

EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing

EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 9.Clinical Decision-Making for Alzheimer Disease Management

EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease

EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease

EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

1. [Dr Snider] Discuss the genetic factors associated with AD. How do mutations in genes such as APP, PSEN1, and PSEN2 contribute to the pathophysiology of the disease? How do different alleles of APOE4affect risk of developing AD?

Related Videos

Related Content

Advertisement

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

Marie Bosslett

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

July 5th 2025

Academic-Community Partnerships Bringing Cancer Care to Patients

Laura Joszt, MA

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

Related Content

Advertisement

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

Marie Bosslett

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

July 5th 2025

Academic-Community Partnerships Bringing Cancer Care to Patients

Laura Joszt, MA

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.